Skip to main content
. 2003 Oct 8;23(27):9107–9115. doi: 10.1523/JNEUROSCI.23-27-09107.2003

Figure 5.

Figure 5.

The effects of MDMA on motor activity (a), motor disability (b), chorea (c), dystonia (d), and dyskinesia (e) in MPTP-treated, l-DOPA-primed common marmosets treated with the selective D2/D3 agonist pramipexole (60 μg/kg). Pramipexole treatment led to a prolonged increase in locomotor activity (a) and improvement in motor disability (b). MDMA dose-dependently inhibited motor activity but did not affect the ability of pramipexole in reducing motor disability. Dyskinesia, chorea (c), and dystonia (d) were dose-dependently inhibited by MDMA.